12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Company News  |  Deals

Wilex, Nestle deal

Wilex exercised an option under a 2011 deal and will receive a $17.5 million payment from Nestle's Prometheus Laboratories Inc. unit in lieu of receiving European rights to commercialize an undisclosed product. Prometheus received U.S. commercialization rights to cancer candidate

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >